Jessica graduated from Curtin University of Technology in 2014 with a double major degree in Journalism and PR. Her first journalism job was at the Kalgoorlie Miner, WA's only regional daily newspaper, where she wrote and later managed the arts, business, history and real-estate sections of the paper. Before Proactive Investors, Jessica wrote for the Australian Mining Review and Australian Energy Review.
Eve Investments, via agreements with THC Global, now has a viable option to access THC’s cannabis licensing for research and development of its products.
The company has a clear path towards leading the Australian cannabis market to produce high-grade pharmaceutical medical cannabis products.
The évolis® professional products can now be imported into EU countries and the UK following comprehensive safety and compliance reviews.
Having secured a substantial growing capacity over two sites and an industry-leading pharmaceuticals bio-manufacturing facility, THC Global is in a prime position to service domestic patients and the export market.
The company uses its proven protected diamagnetic microarray technology in both skin care and joint inflammation products.
The positive data comes as Orthocell is active in partnering discussions and will support the company to gain traction in key markets.
Monash Health will be the second clinical trial site with the company expecting to sign further hospitals to join the ColoSTAT trial in coming weeks.
In parallel with the global roll-out of PromarkerD to markets, the company is pursuing registration of the kit version of the test for larger-scale adoption.